Skip to content

Search

Showing results for "early lung health"

Unique twin study reveals clues to childhood allergies

A study published in Science Advances has revealed that while genetics play a significant role in shaping children's immune systems, environmental factors also influence key immune responses, offering opportunity for preventing allergic diseases.

A life of caring and a passion to give - local legend Harvey Coates

Over 20 years Professor Harvey Oates has made financial contributions to The Kids totaling over 6 figures, as well as sitting on the board for 16 years.

Toddler Talk

A child's ability to communicate is one of their most important developmental achievements. It builds a foundation for everything that is to come.

Toddlers and diabetes

Caring for a child with type 1 diabetes is challenging, and perhaps even more so when the child is a toddler. Mindful of this and considering the unique needs of families caring for very young children with type 1 diabetes, PCH's Diabetes Clinic is currently

Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia

Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children.

RSV: The Hidden Virus

Despite respiratory syncytial virus (RSV) being the leading cause of hospitalisations in the first year of life, there is currently no routine preventative option for otherwise healthy babies.

Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024

Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. 

The Changing Detection Rate of Respiratory Syncytial Virus in Adults in Western Australia between 2017 and 2023

The incidence of respiratory syncytial virus (RSV) in adults is inadequately defined and the impact of SARS-CoV-2-related non-pharmaceutical interventions (NPIs) is underexplored. Using laboratory data, we described the detection rate of RSV in adults ≥16 years in Western Australia (WA) between 2017 and 2023.

Respiratory Syncytial Virus Reinfections in Children in Western Australia

Respiratory syncytial virus (RSV) reinfection in children is poorly understood. We examined the incidence, characteristics, and outcomes of hospital-attended RSV reinfections in children <16 years in Western Australia between 2012 and 2022.

Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19

Respiratory syncytial virus (RSV) remains a leading cause of mortality and morbidity worldwide. RSV seasonality was disrupted by COVID-19-associated nonpharmaceutical interventions (NPIs). We review RSV seasonality, molecular epidemiology, clinical manifestations, and community awareness to inform future prevention strategies.